GDRX
Goodrx Holdings Inc
NASDAQ: GDRX · HEALTHCARE · HEALTH INFORMATION SERVICES
$2.61
-4.75% today
Updated 2026-06-03
Market cap
$897.49M
P/E ratio
44.17
P/S ratio
1.14x
EPS (TTM)
$0.06
Dividend yield
—
52W range
$2 – $6
Volume
1.6M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F4.5
Quality
C5.0
Profitability
C+4.7
Valuation
C4/9
Piotroski F-Score
Moderate
0.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.18
+21.88%
12-Month target
$1.84
-29.50%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy8 Hold0 Sell2 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $10.70M — positive
Risks
- Altman Z 0.20 — distress zone
- Thin margins at 2.61%
- Revenue declining -4.40% QoQ
- P/E 44.17x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $766.55M | $750.26M | $792.32M | $796.85M | $787.89M |
| Net income | $-32.83M | $-8.87M | $16.39M | $30.44M | $1.17M |
| EPS | — | — | — | — | $0.06 |
| Free cash flow | $91.57M | $82.53M | $113.55M | $164.38M | $10.70M |
| Profit margin | -4.28% | -1.18% | 2.07% | 3.82% | 2.61% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-15 | MCGINNIS, CHRISTOPHER A | Sale | 44,779 | — |
| 2026-05-15 | MCGINNIS, CHRISTOPHER A | Buy | 44,779 | — |
| 2026-05-15 | MCGINNIS, CHRISTOPHER A | Sale | 19,726 | $2.49 |
Peer comparison
Smart narrative
Goodrx Holdings Inc trades at $2.61. representing a P/E of 44.17x trailing earnings. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.20, it sits in the distress. TTM revenue stands at $787.89M. with profit margins at 2.61%.
Frequently asked questions
What is Goodrx Holdings Inc's stock price?
Goodrx Holdings Inc (GDRX) trades at $2.61, on a P/E of 44.2x and a P/S of 1.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Goodrx Holdings Inc overvalued?
Goodrx Holdings Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Goodrx Holdings Inc (GDRX)?
The 12-month analyst consensus target is $3.18, about 21.9% above the current $2.61. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of GDRX by 2030?
Our research-backed model puts the 2030 base case at $8.54, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Goodrx Holdings Inc's revenue?
Goodrx Holdings Inc's trailing twelve-month revenue is $787.89M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Goodrx Holdings Inc's Altman Z-Score is 0.20, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryHEALTH INFORMATION SERVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.14x
ROE3.30%
Beta1.62
50D MA$2.42
200D MA$2.97
Shares out0.10B
Float0.09B
Short ratio—
Avg volume1.6M
Performance
1 week+0.00%
1 month+15.64%
3 months+25.45%
YTD+3.69%
1 year—
3 years—
5 years—